IN2012DN00250A - - Google Patents
Info
- Publication number
- IN2012DN00250A IN2012DN00250A IN250DEN2012A IN2012DN00250A IN 2012DN00250 A IN2012DN00250 A IN 2012DN00250A IN 250DEN2012 A IN250DEN2012 A IN 250DEN2012A IN 2012DN00250 A IN2012DN00250 A IN 2012DN00250A
- Authority
- IN
- India
- Prior art keywords
- complexes
- purified
- protein complexes
- provides
- peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract 2
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract 2
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000013592 cell lysate Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000004255 ion exchange chromatography Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0910591.7A GB0910591D0 (en) | 2009-06-19 | 2009-06-19 | Method for the purification of protein complexes |
| PCT/GB2010/051023 WO2010146401A1 (fr) | 2009-06-19 | 2010-06-21 | Méthode de purification de complexes de protéines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00250A true IN2012DN00250A (fr) | 2015-05-01 |
Family
ID=40941082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN250DEN2012 IN2012DN00250A (fr) | 2009-06-19 | 2010-06-21 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10040820B2 (fr) |
| EP (1) | EP2442825B1 (fr) |
| JP (1) | JP5778666B2 (fr) |
| CN (1) | CN102458460B (fr) |
| AU (1) | AU2010261505B2 (fr) |
| GB (1) | GB0910591D0 (fr) |
| IN (1) | IN2012DN00250A (fr) |
| WO (1) | WO2010146401A1 (fr) |
| ZA (1) | ZA201200420B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013008738B1 (pt) * | 2010-10-11 | 2017-12-19 | Abbvie Bahamas Ltd. | Method for purification of a protein |
| GB201104897D0 (en) | 2011-03-23 | 2011-05-04 | Immunobiology Ltd | Method for the production of protein complexes and vaccine compositions comprising the same |
| US20140255449A1 (en) * | 2011-07-21 | 2014-09-11 | Biotech Tools S.A. | Dosage of dnak |
| EP3635091B1 (fr) * | 2017-06-07 | 2024-04-10 | University of Maryland, Baltimore County | Usine sur puce pour la production de médicaments/bioproduits/bioproduits biologiques/agents biothérapeutiques d'origine biologique |
| KR102270048B1 (ko) * | 2020-07-10 | 2021-06-28 | 주식회사 녹십자 | 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| EP0851765A4 (fr) * | 1995-09-13 | 2000-01-19 | Univ Fordham | Procedes therapeutique et profilactique utilisant des proteines du choque thermique |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| GB9818133D0 (en) | 1998-08-19 | 1998-10-14 | Quadrant Holdings Cambridge | Vaccine |
| GB9919733D0 (en) | 1999-08-19 | 1999-10-20 | Colaco Camilo | Vaccines against intracellular pathogens |
| GB9919734D0 (en) | 1999-08-19 | 1999-10-20 | Colaco Camilo | Vaccines from infectious agents |
| AUPQ233799A0 (en) | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
| GB0021757D0 (en) | 2000-09-04 | 2000-10-18 | Colaco Camilo | Vaccine against microbial pathogens |
| WO2002028407A1 (fr) | 2000-09-29 | 2002-04-11 | University Of Connecticut Health Center | Procedes destines a recuperer des proteines de choc thermique et des complexes de ces proteines |
| US20020172682A1 (en) * | 2000-10-20 | 2002-11-21 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
| US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
| US6875849B2 (en) | 2001-05-01 | 2005-04-05 | Arizona Board Of Regents Of Behalf Of The University Of Arizona | Methods of recovering chaperone proteins and complexes thereof |
| CN1665533A (zh) | 2002-05-02 | 2005-09-07 | 康涅狄格大学健康中心 | 热激蛋白用于增强抗体疗法功效的用途 |
| EP1531160B1 (fr) * | 2003-11-12 | 2010-12-29 | Alfa Biogene International B.V. | Récupération d'une proteine de choc thermique |
| GB0816242D0 (en) * | 2008-09-05 | 2008-10-15 | Immunobiology Ltd | Method of purifying protien complexes |
-
2009
- 2009-06-19 GB GBGB0910591.7A patent/GB0910591D0/en not_active Ceased
-
2010
- 2010-06-21 US US13/378,808 patent/US10040820B2/en active Active
- 2010-06-21 EP EP10732406.3A patent/EP2442825B1/fr active Active
- 2010-06-21 WO PCT/GB2010/051023 patent/WO2010146401A1/fr not_active Ceased
- 2010-06-21 IN IN250DEN2012 patent/IN2012DN00250A/en unknown
- 2010-06-21 AU AU2010261505A patent/AU2010261505B2/en not_active Ceased
- 2010-06-21 JP JP2012515567A patent/JP5778666B2/ja not_active Expired - Fee Related
- 2010-06-21 CN CN201080031703.0A patent/CN102458460B/zh active Active
-
2012
- 2012-01-18 ZA ZA2012/00420A patent/ZA201200420B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10040820B2 (en) | 2018-08-07 |
| US20120135029A1 (en) | 2012-05-31 |
| EP2442825A1 (fr) | 2012-04-25 |
| WO2010146401A1 (fr) | 2010-12-23 |
| AU2010261505A1 (en) | 2012-01-19 |
| CN102458460A (zh) | 2012-05-16 |
| AU2010261505B2 (en) | 2015-02-05 |
| ZA201200420B (en) | 2018-11-28 |
| CN102458460B (zh) | 2018-01-30 |
| JP2012530123A (ja) | 2012-11-29 |
| GB0910591D0 (en) | 2009-07-29 |
| EP2442825B1 (fr) | 2017-11-08 |
| JP5778666B2 (ja) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00452A (fr) | ||
| MX2024014468A (es) | Anticuerpos anti-cd63, conjugados y usos de estos | |
| MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
| MX2012011405A (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY173004A (en) | Mycobacterial antigen vaccine | |
| EA201991059A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| EA201071297A1 (ru) | Новые и действенные пептиды мнс ii класса, полученные из сурвивина | |
| MX2009006760A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas. | |
| MX2014004359A (es) | Proteina naglu humana recombinante y usos de la misma. | |
| MX363307B (es) | Plataformas para suministro de antigenos. | |
| MY156286A (en) | Human il-23 antigen binding proteins | |
| MX2019003615A (es) | Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas. | |
| WO2012069568A3 (fr) | Peptides immunogènes destinés à la prévention et/ou au traitement de maladies infectieuses, de maladies auto-immunes, de réponses immunitaires aux allofacteurs, de maladies allergiques, de tumeurs, du rejet de greffe, et des réponses immunitaires dirigées contre des vecteurs viraux utilisés en thérapie génique ou en vaccination génique | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| EP4296673A3 (fr) | Peptides et procédés pour la détection d'anticorps de la maladie de lyme | |
| EA201290675A1 (ru) | Вакцинные векторы и способы усиления иммунных ответов | |
| IN2014DN10288A (fr) | ||
| NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| EA201390676A1 (ru) | Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |